Clinical Trial Update: Treatment Protocol for Relapsed Acute Promyelocytic Leukemia (APL) With Arsenic [Phase 4]

View source ↗

Summary

This clinical trial update describes a Phase 4 treatment protocol using arsenic trioxide for relapsed or refractory acute promyelocytic leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: German AML Cooperative Group | Conditions: Relapsed Acute Promyelocytic Leukemia, Refractory Acute Promyelocytic Leukemia | Phase 4 | Status: UNKNOWN